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The kainic acid receptors belong to the class of ionotropic glutamate receptors and comprise five subunits
named GluK1–5. Radioligands are essential tools for use in binding assays aimed at ligand–receptor
structure–activity-relationship studies. Previous work has led to the synthesis of GluK1 radioligands [3H]-
SYM2081, [3H]-UBP310 and [3H]-ATPA, however all strategies were work-intensive and thus not attractive.
Herein, we report the synthesis of [3H]-NF608 and subsequent pharmacological evaluation at homomeric
recombinant rat GluK1 receptors. Binding affinities of a series of standard GluK1 ligands were shown to be
in line with previously reported affinities obtained by use of already reported radioligands.
Introduction
The kainic acid (KA, Fig. 1A) receptors belong to the class of
ionotropic glutamate receptors and are believed to mediate a
modulatory excitatory response in the central nervous system.
The KA receptors comprise five subunits, termed GluK1–5 and
are tetrameric in structure (dimer of dimers). While the subunits
GluK1–3 may form functional homomeric as well as heteromeric
receptors, subunits GluK4,5 only form functional receptors with
GluK1–3. To study the role and function of each of the KA recep-
tor subtypes, it is essential that subtype selective ligands (phar-
macological tools) are available. While selective GluK1 agonists
and antagonists have been reported (Fig. 1B), selective ligands
for the GluK2–5 subtypes remain to be discovered.1,2 In order to
achieve this, extensive structure–activity-studies are continuously
performed, which includes binding affinity studies of synthe-
sized compounds at homomeric, recombinant KA receptor sub-
types. Readily accessible radioligands are essential to accomplish
this, and previous work-intensive strategies have led to the syn-
thesis of [3H]-UBP3103 and [3H]-ATPA (ref. 4) (Fig. 1C) as GluK1-
selective radioligands. The high affinity KA receptor ligand
SYM2081 (Fig. 1C) has also been employed as the radioligand in
binding assays of homomeric GluK1–3 receptors,5 however its
difficult purification makes it less attractive to produce and it is
no longer commercially available. While commercially available
[3H]-KA can be successfully used in radioligand binding studies
for GluK2 (Kd = 6.5 nM) (Fig. 2), GluK3 (Kd = 8.0 nM) (Fig. 2),
GluK4 LBD (Kd = 1.9 nM) (Kristensen et al., 2016)
17 and
GluK5 (Kd = 6.9 nM) (Møllerud et al., 2016)
16 it has 10-fold
lower affinity at GluK1 (Kd = 67 nM) (Fig. 2) making it a less
than ideal radiolabel for binding studies at GluK1. Here we re-
port the synthesis and pharmacological characterization of [3H]-
NF608 – a new high affinity, GluK1-selective radioligand.
Results and discussion
Synthesis
Firstly, we pursued a direct bromination of commercially
available UBP310 to obtain the dibromothiophene precursor
previously reported for the synthesis of [3H]-UBP310 (Scheme
S1, ESI‡).3 However, bromination took place at the uracil ring
only, and all attempts failed to following incorporate deute-
rium (see ESI‡ for details).
We next turned to investigate the high affinity, selective
GluK1 ligand NF608 (Fig. 1) which also comprises a thio-
phene ring. Its synthesis is described in only two steps from
commercially available thienoĳ3,2-d]pyrimidine-2,4Ĳ1H,3H)-
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dione (1) (Scheme 1).7 Firstly, we attempted bromination of
the thiophene ring of 3 under standard conditions (Br2 in
AcOH or TFA, rt to 90 °C) (Scheme 1). However, none of the
corresponding bromo or dibromo derivatives comprised by
general structure 4 were observed but only the expected cleav-
age of the BOC group.
We therefore revised the strategy to introduce the bromine
functionality earlier in the synthesis (Scheme 1), and indeed
we were able to brominate the thiophene ring of 1 in the 7
position to give 5. Disappointingly, alkylation at N1 with lac-
tone 2 (ref. 12) as the electrophile was unproductive (NaH,
DMF, −65 to 80 °C) presumably due to the bulkiness of the
bromine atom (Scheme 1). For that reason, we turned to pur-
sue bromination of the 6 position of the thienopyrimidine
ring in order to allow for following alkylation at N1.
The synthesis of key bromo intermediate 13 (Scheme 2)
commenced with N-protection of commercially available
methyl 3-aminothiophene-2-carboxylate (7) with
trichloroacetyl isocyanate in THF to afford compound 8 in
93% yields.13 Subsequent bromination with Br2 in acetic acid
at 80 °C successfully provided exclusively 5-bromo-thiophene
9, which was then treated with 2 M ammonia in methanol to
afford urea 10.13 Cyclization with potassium tert-butoxide in
DMF, furnished the desired heterocyclic product 11.13 Alkyl-
ation at N1 with lactone 212 was performed using sodium
hydride as base in DMF, as described in a similar proce-
dure.7 The alkylation product 12 was obtained in only 18% –
a yield which could likely be optimized. Cleavage of the
BOC group in the presence of 2 M aq HCl provided key
bromo amino acid intermediate 13, in overall 6 steps. Deuter-
ation over Pd/C in a basic aqueous media gave 80% deute-
rium incorporation, furnishing deuterated product [D6]-
NF608 together with NF608, in overall 57% yield.
Tritiation
Having established the method for deuterium incorporation,
tritiation was carried out by use of T2 (gas) with Pd/C as cata-
lyst in water to give [3H]-NF608 in high yield (Scheme 3) at a
specific activity of 16.3 Ci mmol−1.
Radiochemical stability
Formulation of [3H]-NF608 was chosen as a 1 mCi mL−1 solu-
tion in H2O–EtOH (1 : 1) and the radiochemical stability was
monitored over time. When stored at −21 °C, the stability
was determined to be 98% after 42 days and 97.5% after 90
days. When stored at −196 °C for 90 days, no decomposition
could be detected.
GluK1 binding pharmacology
Assay validation
Based upon our previous publication we anticipated [3H]-
NF608 to be a high affinity radioligand at GluK1 since
unlabeled NF608 had shown a Ki of 5.3 nM.
7 Initial tests indi-
cated high level of specific binding of the radiolabel to homo-
meric rat GluK1 expressed in sf9 cell membranes and subse-
quently an assay validation was conducted using 1 mM (S)-
glutamate to define nonspecific binding. No specific binding
was seen using uninfected sf9 cell membranes. A series of
buffers, temperatures, pH conditions and washing protocols
were evaluated (Table 1) and 50 mM Tris-HCl pH 7.1 at 4 °C
with 2 × 4 mL filter washes was found to be optimal for spe-
cific binding to GluK1. There was no pH dependency of the
binding between pH 7.1 and 7.8. Binding of [3H]-NF608 to
native GluK1 in rat brain P2 membranes was tested using the
high affinity GluK1-selective ligand 10 μM UBP310 to evaluate
nonspecific binding and, although a small amount of specific
binding was detected, it was insufficient to perform pharma-
cological analyses at native GluK1. This is likely due to the
low specific activity of the radioligand (16.3 Ci mmol−1).
Kinetics
The association and dissociation kinetics of [3H]-NF608 bind-
ing were examined at GluK1 at 4 °C (Fig. 3). The association
Fig. 1 A) Chemical structure of kainic acid (KA). B) Reported high affinity subtype selective GluK1 ligands UBP310,6 NF608,7 (S)-ATPA,8 (S)-E-
neopentylidene Glu,9 and (2S,4R)-4-(3-hydroxyĲmethyl)amino-3-oxopropyl)glutamic acid.10 C) Reported tritium labeled high affinity GluK1 ligands,
[3H]-UBP310,3 [3H]-ATPA,4 and [3H]-SYM2081.11
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rate was measured as (mean ± SEM) kon = 10.05 ± 1.30 × 10
6
min−1 nM−1 (n = 3) and the dissociation rate determined as
(mean ± SEM) koff = 0.0274 ± 0.0017 min
−1 (n = 4). The time
course of binding at 4 °C indicated that equilibrium is
attained by 1 h. Calculation of the affinity from the kinetic
rate constants gave a kinetic Kd (mean ± SEM) = 2.72 ± 0.39
nM, which agrees well with the previously determined affinity
of NF608 at GluK1 (Ki = 5.29 ± 0.66 nM).
7
Saturation
The equilibrium binding affinity of [3H]-NF608 at GluK1 was
measured in saturation binding (Fig. 4) where (mean ± SEM,
n = 3) Kd = 6.68 ± 0.88 nM, Bmax = 5829 ± 248 fmol mg
−1 pro-
tein. This affinity is not statistically significantly different (p
= 0.251, t-test) from our previously determined affinity of
NF608 at GluK1 using [3H]SYM2081 as the radioligand.
Competition
The pharmacological profile of a selected series of KA recep-
tor ligands was examined using [3H]-NF608 (Fig. 5). A com-
parison of the profile to that previously observed using [3H]
SYM2081 as the radioligand7 shows reasonable agreement
and Hill values are near unity for all ligands tested (Table 2).
Analysis of homologous competition binding with NF608
yielded a Kd = 6.93 nM (pKd = 8.160 ± 0.047) (Fig. 6), which is
identical to the Kd determined from saturation analysis.
Conclusion
In conclusion we have reported a short and efficient method
for the radiosynthesis of the selective GluK1 radioligand [3H]-
NF608. The radioligand was characterized in in vitro binding
assays at cloned homomeric GluK1 receptors and binding af-
finities (Ki) of a series of standard GluK1 ligands were shown
to be in line with previously reported affinities obtained by
use of already reported radioligands.
Experimental section
Chemistry
All reactions involving dry solvents or sensitive agents were
performed under a nitrogen or argon atmosphere, and glass-
ware was dried prior to use. Commercially available
chemicals were used without further purification. Solvents
were dried prior to use with an SG water solvent purification
system or dried by standard methods. Reactions were moni-
tored by analytical thin-layer chromatography (TLC, Merck
silica gel 60 F254 aluminum sheets), analytical HPLC or
UPLC. Flash chromatography was carried out using the
Merck silica gel 60 (15–40 μm) or Merck silica gel 60 (40–63
μm). 1H NMR spectra were recorded on a 400 MHz Bruker
Avance III or 600 MHz Bruker Avance III HD, and 13C NMR
spectra on a 101 MHz Bruker Avance III or 151 MHz Bruker
Avance III HD. Chemical shifts are reported in δ (ppm) rela-
tive to the singlet at δ = 7.26 ppm of CDCl3, the quintet at
2.50 ppm of DMSO-d6, and the singlet at 4.79 ppm of D2O for
1H NMR, and to the centre line of the triplet at δ = 77.16
ppm of CDCl3, the heptuplet at 39.52 ppm of DMSO-d6 for
13C-NMR. Analytical HPLC was performed using a Dionex Ul-
tiMate 3000 pump and Dionex Ultimate 3000 Diode Array De-
tector (200, 210, 225 and 254 nm) installed with a Phenom-
enex Gemini-NX 3μ C18 110A, 250 × 4.60 mm column.
Fig. 2 Homologous competition binding of [3H]KA at recombinant,
homomeric rat GluK1–3 expressed in sf9 cell membranes. [3H]KA (44.0
Ci mmol−1) concentrations (nM) are indicated in the figure insets.
GluK1 pKd = 7.173; GluK2 pKd = 8.185; GluK3 pKd = 8.097. Hill values
are close to unity for all. Shown are pooled data (mean ± SEM) from
single experiments conducted in triplicate.
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Solvent A: H2O + 0.1% TFA; solvent B: MeCN–H2O 9 : 1 +
0.1% TFA. For HPLC control, data collection and data han-
dling, Chromeleon software v. 6.80 was used. Preparative
HPLC was carried out on an Ultimate 3000 Thermo SCIEN-
TIFIC system with a Dionex Ultimate 3000 series pump, a
Dionex Ultimate 3000 Diode Array Detector (200, 210, 225
and 254 nm), and a Phenomenex Gemini-NX 5μ C18 110A,
250 × 21.20 mm column for preparative purifications or a
Phenomenex Gemini-NX 5μ C18 110A, 250 × 10.00 mm col-
umn for semi-preparative purifications. Solvent A: H2O +
0.1% TFA; solvent B: MeCN–H2O 9 : 1 + 0.1% TFA. For HPLC
control, data collection and data handling, Chromeleon soft-
ware v. 6.80 was used. UPLC-MS spectra were recorded using
an Acquity UPLC H-Class Waters series solvent delivery sys-
tem equipped with an autoinjector coupled to an Acquity
QDa and TUV detectors installed with an Acquity
UPLC®BECH C18 1.7 μm column. Solvent A: 5% aq MeCN +
0.1% HCO2H: solvent B: MeCN + 0.1% HCO2H. Usually, gra-
dients from A : B 1 : 0 to 0 : 1 (5 min) or A : B 1 : 0 to 0 : 50 (5
Scheme 1 Attempted bromination of 3 to give bromo-analogs comprised by general structure 4. Reagents and conditions. a) NaH, DMF, −65 to
80 °C; b) Br2, AcOH or TFA, rt to 90 °C (only the HCl or TFA salt of NF608 was observed) c) Br2, AcOH, 90 °C (97%).
Scheme 2 Synthesis of key 6-bromo precursor 13 and incorporation of deuterium to give [D6]-NF608. Reagents and conditions. (a)
Trichloroacetyl isocyanate, THF, 0 °C to rt, 2 h, 93%; (b) Br2, acetic acid, 0–80 °C, overnight, 69%; (c) 2 N NH3 in methanol, 0 °C to rt, 30 min, 89%;
(d) tert-BuOK, DMF, rt, overnight, 95%; (e) NaH, DMF, 0 °C to rt, then lactone 2 in DMF, 0 °C to rt, 18% (f) 2 M aq HCl, 50 °C, 1 h, 94% (g) D2 (g),
Pd/C, NaOH, H2O, rt, overnight, 57%.
Scheme 3 Tritiation of 13. Reagents and conditions. a) T2 (515 mbar),
Pd/C (30%), NaOH (1 M), H2O, 3 h, r.t. [23.5 mCi (>99.9% R.C.P.), 23%
R.C.Y.]
MedChemComm Research Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
Se
pt
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
4/
03
/2
01
7 
12
:0
2:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
2140 | Med. Chem. Commun., 2016, 7, 2136–2144 This journal is © The Royal Society of Chemistry 2016
min), were performed depending on the polarity of the com-
pounds. For data collection and data handling, MassLynx
software was used. Compounds were dried under high vac-
uum or freeze dried using a ScanVac Cool Safe Freeze Drier.
The purity of compounds submitted for pharmacological
characterization was determined by 1H-NMR and HPLC to be
>95%.
For the tritiation experiments
1H-, 3H- and 13C NMR spectra were recorded at 300/320 MHz
and 75 MHz, respectively, with a Bruker Avance II 300 MHz
instrument at 25 °C. The residual solvent signals in the 1H
and 13C NMR spectra were used as an internal reference
(CDCl3: δ = 7.26 for
1H and δ = 77.23 for 13C). The mass spec-
tra were obtained by the Bruker Daltonics Esquire 4000 sys-
tem with a direct input (ESI, stream ACN–H2O, a mass range
of 50–1200 Da, Esquire Control Software). The HR-mass spec-
tra were obtained in the ESI mode either on a Waters-
Table 1 Binding assay conditions evaluated
Buffers (50 mM)
Tris-HCl
Tris-HCl + 100 mM NaCl
Bis-Tris-HCl
Na+HEPES
Na+MOPS
Na+TES
NaH2PO4
Na+PIPES
pH
7.1
7.4
7.6
7.8
Temperature (°C)
4
22
37
Filter washing (mL)
2 × 3
3 × 3
2 × 4
3 × 4
2 × 5
3 × 5
Overview of the various assay conditions tested. The pH, temperature
and washing conditions were only evaluated using 50 mM Tris-HCl
buffer.
Fig. 3 Association and dissociation kinetic experiments of [3H]-NF608
binding to recombinant, homomeric rat GluK1 expressed in sf9 cell
membranes. Dissociation was initiated after a 2 h equilibration with the
radioligand. Shown are pooled, normalized data from 3–4 experiments
conducted in triplicate. Nonspecific binding was determined in the
presence of 1 mM (S)-glutamate.
Fig. 4 Saturation binding of [3H]-NF608 (16.3 Ci mmol−1) to
recombinant, homomeric rat GluK1 expressed in sf9 cell membranes.
Shown are pooled, normalized data from 3 experiments conducted in
triplicate. Nonspecific binding was determined in the presence of 1
mM (S)-glutamate. From the pooled analysis: Kd = 6.61 ± 0.50 nM,
Bmax = 4675 ± 76 fmol mg
−1 protein, nH = 1.07 ± 0.07.
Fig. 5 Competition binding at recombinant, homomeric rat GluK1
expressed in sf9 cell membranes. Shown are pooled, normalized data
from 3 experiments conducted in triplicate. DA, domoic acid; ATPA,
(RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid;
KA, kainic acid; QA, quisqualic acid; Glu, (S)-glutamic acid; UBP310,
(S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-thiophene-3-yl-methyl)-
5-methylpyrimidine-2,4-dione.
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Micromass Q-TOF Micro mass spectrometer or on a Thermo
Fisher Scientific LTQ Orbitrap XLc. The tritiation reaction
was performed on a custom-designed tritium manifold sys-
tem manufactured by RC Tritec AG, Switzerland. Activities
were measured on a Perkin-Elmer TriCarb 2900TR liquid
scintillation counter (LSC) in a Zinsser Quicksafe A cocktail.
The HPLC was performed on a system consisting of a WA-
TERS Delta 600 Pump and Controller, a WATERS 2487 UV de-
tector and a RAMONA radio chromatographic detector from
Raytest (Germany) with interchangeable fluid cells. For the
preparative runs, the cell with a single small crystal of solid
scintillator was used; for analytical runs, the column effluent
was mixed with a Zinsser Quickszint Flow 302 cocktail at the
ratio of 1 : 3.
tert-Butyl (S)-(2-oxooxetan-3-yl)carbamate (2). To an ice-
cooled solution of triphenylphosphine (95%, 7.3 g, 26.53
mmol) in anhydrous THF (50 mL), was added diethyl azidodi-
carboxylate (DEAD, 97%, 4.6 mL, 28.95 mmol). The resulting
solution was stirred at 0 °C for 15 minutes and a solution of
N-(tert-butoxycarbonyl)-L-serine (99%, 5 g, 24.12 mmol) in an-
hydrous THF (36 mL) was added dropwise. The reaction mix-
ture was stirred and allowed to reach room temperature over-
night. Next day, the mixture was quenched with water (80
mL) and then it was diluted with EtOAc (40 mL). The aque-
ous layer was extracted with EtOAc (3 × 80 mL) and the col-
lected organic layers were washed with brine (80 mL), dried
over MgSO4 and filtered. After that, the solvent of the filtrate
was removed under reduced pressure to give a residue that
was purified by flash chromatography (silica gel, heptane–
EtOAc 95 : 5 to 7 : 3, gradient) to afford the lactone 2 as a
white solid (1.7 g, 37%). 1H NMR (600 MHz, CDCl3) δ 5.26
(br s, 1H), 5.20–5.05 (m, 1H), 4.47 (br t, J = 5.1 Hz, 1H), 4.43
(br t, J = 4.7 Hz, 1H), 1.48 (s, 9H). Product described in ref.
12.
(S)-1-((2′-tert-Butoxycarbonyl)amino-2′carboxyethyl)thieno-
ĳ3,2-d]pyrimidin-2,4-dione (3). A solution of thienoĳ3,2-
d]pyrimidin-4Ĳ3H)-one (98%, 1 g, 5.88 mmol) in anhydrous
DMF (40 mL) was cooled to 0 °C and then sodium hydride
(60% w/w in mineral oil, 214 mg, 5.34 mmol) was added. The
resulting suspension was stirred 50 minutes at room temper-
ature. After that time, the reaction mixture was cooled again
to 0 °C and a solution of tert-butyl (S)-(2-oxooxetan-3-
yl)carbamate (2) (1 g, 5.34 mmol) in anhydrous DMF (20 mL)
was added. The resulting mixture was stirred at room temper-
ature overnight. Then, the reaction mixture was quenched by
adding water dropwise until no reaction was observed. The
solvent of the reaction mixture was co-evaporated with tolu-
ene (3 × 20 mL) to get a white solid that was divided in 6 por-
tions and each one was dissolved in DMSO–MeCN (15 : 1, 1
mL) and purified by 6 consecutive preparative HPLC purifica-
tions (Rt: 19.53 min; flow: 10 mL min−1; A–B 1 : 0 to 25 : 75
(25 min); A–B 25 : 75 (5 min); preferably λ = 254 nm, since
DMSO does not absorb) to afford the desired compound 3 as
a white solid (206 mg, 11%), recovering also the starting
material thienoĳ3,2-d]pyrimidin-4Ĳ3H)-one (Rt: 14.29 min; 109
mg, 11%). 1H NMR (600 MHz, DMSO-d6) δ 12.99 (s, 1H),
11.49 (s, 1H), 8.10 (d, J = 5.4 Hz, 1H), 7.29 (d, J = 5.4 Hz, 1H),
7.01 (d, J = 8.6 Hz, 1H), 4.45–4.36 (m, 2H), 4.03 (dd, J = 15.3,
11.0 Hz, 1H), 1.20 (s, 9H). 13C NMR (151 MHz, DMSO-d6) δ
171.2, 158.2, 155.1, 151.3, 147.9, 135.1, 118.1, 112.2, 78.3,
51.1, 46.5, 27.8. UPLC-MS (m/z) calcd for C14H17N3O6S [M −
H]−, 354.1; found, 354.0.
Table 2 Pharmacological profile of GluK1 ligands at recombinant, homomeric rat GluK1 expressed in sf9 cell membranes
Radioligand → [3H]-SYM2081 [3H]-NF608
Competitor ↓ Ki (nM) nH Ki (nM) nH
(S)-NF608 5.29 ± 0.66a 0.99 ± 0.03 9.9 ± 2.6 0.96 ± 0.04
UBP310 22.1 ± 4.6b 0.78 ± 0.03 44.6 ± 6.6 0.81 ± 0.03
(RS)-ATPA 2.13 ± 0.21 0.96 ± 0.03 11.9 ± 4.6 1.04 ± 0.06
Kainic acid 76 ± 12a 0.99 ± 0.04 135 ± 5 1.01 ± 0.02
Quisqualic acid 171 ± 93c 0.93 ± 0.03 344 ± 72 1.00 ± 0.03
Domoic acid 1.11 ± 0.20c 0.99 ± 0.04 6.41 ± 2.48 1.04 ± 0.01
(S)-Glutamic acid 140 ± 3a 0.98 ± 0.03 292 ± 24 1.30 ± 0.08
Shown are means ± SEM of at least 3 experiments conducted in triplicate at 12–16 ligand concentrations.a Ref. 7. b Ref. 15. c Ref. 5.
Fig. 6 Homologous competition binding of [3H]-NF608 vs. NF608 at
recombinant, homomeric rat GluK1 expressed in sf9 cell membranes.
Shown are means ± SEM of triplicate values normalized for the
maximum specific binding in each individual experiment. Nonspecific
binding is determined using 1 mM (S)-glutamate. Inset: [3H]-NF608
concentrations (nM). Analysis of the pooled data to solve for a
common ligand affinity when the nonspecific binding is fixed at zero%
and the Bmax is floated gave (mean ± SEM) Kd = 6.93 nM (pKd = 8.160
± 0.047). Solving for a common hill value gave (mean ± SEM) nH =
0.9899 ± 0.0455.
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Methyl 3-(3-(2,2,2-trichloroacetyl)ureido)thiophene-2-car-
boxylate (8); methyl 5-bromo-3-(3-(2,2,2-trichloroacetyl)-
ureido)thiophene-2-carboxylate (9). Methyl 3-(3-(2,2,2-
trichloroacetyl)ureido)thiophene-2-carboxylate (8); methyl
5-bromo-3-(3-(2,2,2-trichloroacetyl)ureido)thiophene-2-carboxyl-
ate (9) were synthesized according to ref. 13.
Methyl 5-bromo-3-ureidothiophene-2-carboxylate (10). To
an ice-cooled suspension of 9 (7.84 g, 17.55 mmol) in anhy-
drous MeOH (70 mL), was added 2 M NH3 solution (in
MeOH, 17.5 mL, 35.09 mmol) and this mixture was stirred at
room temperature for 30 minutes, during which time a white
solid precipitated. After this period, the white solid was fil-
tered and washed with cold MeOH (3 × 10 mL) to give the
compound 10 (4.37 g, 89%) as a white solid with a purity of
98% (determined by 1H-NMR). 1H NMR (400 MHz, DMSO-d6)
δ 9.23 (s, 1H), 8.06 (s, 1H), 6.86 (br s, 2H), 3.80 (s, 3H). Prod-
uct described in ref. 13.
6-Bromothienoĳ3,2-d]pyrimidine-2,4Ĳ1H,3H)-dione (11).
6-Bromothienoĳ3,2-d]pyrimidine-2,4Ĳ1H,3H)-dione (11) was
synthesized according to literature procedure.13
(S)-3-(6-Bromo-2,4-dioxo-3,4-dihydrothieno ĳ3,2-d]-
pyrimidin-1Ĳ2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoic
acid (12). A solution of 6-bromothienoĳ3,2-d]pyrimidine-
2,4Ĳ1H,3H)-dione (11) (581 mg, 2.35 mmol) in anhydrous
DMF (11.4 mL) was cooled to 0 °C and then sodium hydride
(60% w/w in mineral oil, 85 mg, 2.14 mmol) was added. The
resulting suspension was stirred 40 minutes at room temper-
ature. After that time, the reaction mixture was cooled again
to 0 °C and a solution of tert-butyl (S)-(2-oxooxetan-3-
yl)carbamate (2) (400 mg, 2.14 mmol) in anhydrous DMF (10
mL) was added. The resulting mixture was stirred at room
temperature overnight. Then, the reaction mixture was
quenched by adding water dropwise until no reaction was ob-
served. The solvent of the reaction mixture was co-evaporated
with toluene (3 × 10 mL) to get a white solid that was divided
into 7 portions and each one was dissolved in DMSO–MeCN
(15 : 1, 1.5 mL) and purified by 7 consecutive preparative
HPLC purifications (Rt: 28.60 min; flow: 10 mL min−1; A (10
min), A–B 75 : 25 to 25 : 75 (25 min), preferably λ = 254 nm be-
cause DMSO do not absorbs) to afford the desired compound
as a white solid (187 mg, 18%). 1H NMR (600 MHz, DMSO-
d6) δ 13.06 (br s, 1H), 11.64 (s, 1H), 7.57 (s, 1H), 7.04 (d, J =
8.9 Hz, 1H), 4.44–4.37 (m, 2H), 3.95 (dd, J = 15.2, 11.0 Hz,
1H), 1.21 (s, 9H). 13C NMR (151 MHz, DMSO-d6) δ 170.9,
157.2, 155.1, 150.9, 147.5, 122.4, 122.1, 112.9, 78.2, 51.1, 46.8,
27.8. UPLC-MS (m/z) calcd for C9H9BrN3O4S [M − Boc]+, 333.9;
found, 333.9.
(S)-2-(6-Bromo-2,4-dioxo-3,4-dihydrothieno ĳ3,2-d]-
pyrimidin-1Ĳ2H)-yl)-1-carboxyethan-1-ammonium chloride
(13). A suspension of (S)-3-(6-Bromo-2,4-dioxo-3,4-
d ihyd ro th ieno ĳ3 ,2 -d ] p y r imid in - 1 Ĳ2H ) - y l ) - 2 - ( ( t e r t -
butoxycarbonyl)amino)propanoic acid (12) (122 mg, 0.28
mmol) in 2 M aq HCl (6 mL), was heated to 50 °C during 1
hour. After that time, the solvent and volatiles were removed
under reduced pressure to afford the title compound as a
white solid (98 mg, 94%), which was used in next reaction
step without further purification. 1H NMR (600 MHz, DMSO-
d6) δ 11.73 (s, 1H), 8.40 (s, 3H), 7.68 (s, 1H), 4.44 (dd, J =
15.0, 6.3 Hz, 1H), 4.27 (dd, J = 15.0, 7.9 Hz, 1H), 4.10 (br t, J =
6.3 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 168.3, 157.2,
151.4, 146.6, 123.0, 121.6, 113.6, 50.5, 44.7. UPLC-MS (m/z)
calcd for C9H9BrN3O4S [M + H]
+, 333.9; found, 333.9.
Sodium (S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-
dihydro-2H-thienoĳ3,2-d]pyrimidin-3-ide-6-d ([D6]-NF608
disodium salt) and sodium (S)-1-(2-amino-2-carboxylatoethyl)-
2,4-dioxo-1,4-dihydro-2H-thienoĳ3,2-d]pyrimidin-3-ide (NF608
disodium salt). Pd/C (1.8 mg, 10% Pd on activated C, water-
wet) was weighed in a small flask that was repeatedly filled
and evacuated with N2 (3 times), and then D2 (3 times). In
parallel, (S)-2-(6-bromo-2,4-dioxo-3,4-dihydrothienoĳ3,2-d]-
pyrimidin-1Ĳ2H)-yl)-1-carboxyethan-1-aminium chloride (13) (9
mg, 0.024 mmol) was weighed in a separate flask that was re-
peatedly filled and evacuated with N2 (3 times). Then, water
(240 μL) and 1 M aq NaOH (69 μL, 0.069 mmol) were added
to afford a suspension that was heated to 60 °C for 5 minutes
until getting a clear solution that was transferred to the previ-
ous flask with Pd/C. The resulting mixture was repeatedly
filled and evacuated with D2 (3 times), and stirred vigorously
at room temperature overnight under D2 (1 atm). After this
period, the reaction mixture was filtered through a plug of
Celite®, and the filtrand was washed with water (3 × 3 mL).
Then, the filtrate was concentrated in vacuo to give the deu-
terated : hydrogenated disodium salts of products [D6]-
NF608 : NF608 in a 4 : 1 ratio, as a white solid (4 mg, 57%,
80% D-incorporation).
Sodium (S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-
dihydro-2H-thienoĳ3,2-d]pyrimidin-3-ide-6-d ([D6]-NF608). 1H
NMR (600 MHz, D2O) δ 7.29 (br s, 1H), 4.29 (d, J = 7.1 Hz,
2H), 3.75 (t, J = 7.1 Hz, 1H). 13C NMR (151 MHz, D2O) δ
178.6, 163.6, 155.3, 148.5, 136.3, 117.1, 113.3, 54.8, 49.0.
UPLC-MS (m/z) calcd for C9H9DN3O4S [M + H]
+, 257.0; found,
257.0.
Sodium (S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-
dihydro-2H-thienoĳ3,2-d]pyrimidin-3-ide (NF608). 1H NMR
(600 MHz, D2O) δ 8.02 (d, J = 5.5 Hz, 1H), 7.29 (d, J = 5.5 Hz,
1H), 4.29 (d, J = 7.1 Hz, 2H), 3.75 (t, J = 7.1 Hz, 1H). 13C NMR
(151 MHz, D2O) δ 178.6, 163.6, 155.3, 148.5, 136.3, 117.2,
113.3, 54.8, 49.0.
[3H]-(S)-2-Amino-3-(2,4-dioxo-3,4-dihydrothienoĳ3,2-d]-
pyrimidin-1Ĳ2H)-yl)propanoic acid ([3H]-NF608). A solution of
13 (1.3 mg, 3.5 μmol) with Pd/C [30%] (2.6 mg, 2 w/w eq.) in
H2O (1 mL) and NaOH (20 μL, 1 M) in round reaction flask
(2 mL) equipped with a Teflon-coated stir bar was mounted
onto tritium manifold system. The reaction mixture was
degassed three times in a repeated freeze–thaw cycle (liquid
nitrogen), and pressure of released tritium gas was adjusted
to 515 mbar (6.9 Ci). The reaction mixture was vigorously
stirred for 3 hours. The reaction mixture was frozen with liq-
uid nitrogen and unreacted tritium gas was reabsorbed in
the uranium bad. The reaction mixture was heated up to
room temperature and the catalyst was filtered off with a
PTFE syringe filter (0.45 μm). The tritiation flask and filter
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were rinsed with H2O (3 × 0.6 mL). To remove labile activity,
the solvent with addition of EtOH (2 mL) was repeatedly ly-
ophilized (3 × 3 mL H2O/EtOH 50 : 50). The activity of crude
product (63% R.C.P.) was determined at 65 mCi. The crude
product was dissolved in H2O (1 mL) and purified by radio-
HPLC on a Synergi 4μ POLAR RP80A 250 × 4.6 mm semi-
preparative column using gradient elution with A = water, B =
acetonitrile (flow of 4.7 mL min−1, 25 °C, 100% of A for 25
min, 100% of B in 35 min). The retention time of [3H]-NF608
was detected at 19.3 min. Pure [3H]-NF608 was isolated in to-
tal activity 23.5 mCi (16.3 Ci mmol−1), 23% R.C.Y. The spe-
cific activity was determined by HRMS at 16.3 Ci mmol−1. 3H-
NMR (320 MHz, D2O): δ 8.08 (1 T, s). HRMS (ESI): calc. for
C9H7
3H1N3O4S [M − 1] 256.0318; found 256.0319.
Pharmacology
Recombinant homomeric rat GluK1ĲQ)1b, GluK2(V,C,R)a and
GluK3a were expressed in sf9 insect cells as previously de-
scribed.5 Rat whole brain (mixed sex) crude synaptosomal
(P2) membranes were prepared by standard methods.14 For
use in binding assays, an aliquot of membranes was thawed
and washed four times by centrifugation 48 000 × g, 15 min
at 4 °C with Ultra-Turrax resuspension in 25 mL ice-cold hy-
potonic buffer (5 mM Tris-HCl, pH 7.4, 4 °C). Membranes
were then resuspended in assay buffer (50 mM Tris-HCl, pH
7.1, 4 °C). Binding assays were conducted in a volume of 250
μL at 4 °C and kinetic and saturation assays terminated by
rapid filtration through 0.3% (w/v) polyethyleneimine-treated
GF/C-type glass fiber filters (VWR filter #696; VWR, Denmark)
on 12-well Millipore filtration manifolds (Millipore, Darm-
stadt, Germany), washing twice with 4 mL ice-cold assay
buffer. Filters were equilibrated in 3 mL EcoScint scintillation
fluid (National Diagnostics, Atlanta, GA) for 12 h and radioac-
tivity detected as DPM using a TriCarb 2900 scintillation
counter (PerkinElmer, Waltham, MA). Non-specific binding
was determined in the presence of 1 mM (S)-glutamate. In
competition experiments, bound and free radioligand were
separated by cold filtration through GF/B glass fiber filters in
UniFilter-96 microtitre plates (PerkinElmer) on a FilterMate
manifold (PerkinElmer) using two washes with ice-cold assay
buffer. Filters were dried 1 hour at 70 °C and 50 μL Micro-
scint 20 (PerkinElmer) was added. Radioactivity was detected
as DPM using a TopCounter (PerkinElmer).
Binding data were analyzed with GraphPad Prism v6
(GraphPad Software, San Diego, CA) using: one-site Ki and
four-parameter logistic equations for competition data, one
site-homologous equation for [3H]kainate Kd determination,
mono-exponential rate equations for association and dissoci-
ation data and one-site total and nonspecific binding for
[3H]-NF608 saturation binding.
Abbreviations
KA Kainic acid
Glu (S)-Glutamic acid
DA Domoic acid
QA Quisqualic acid
NF608 (S)-2-Amino-3-(2,4-dioxo-3,4-dihydrothieno[3,2-d]
pyrimidin-1(2H)-yl)propanoic acid
ATPA (RS)-2-Amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)
propanoic acid
UBP310 (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxy-
thiophene-3-yl-methyl)-5-methylpyrimidine-2,4-
dione
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